C4 Therapeutics Enters New Partnership with Roche for Degrader-Antibody Conjugate (DAC) Development, Reports Strong Q2

C4 Therapeutics, Inc. USA

Overview

C4 Therapeutics (C4T) reported robust financial results for Q2 2026 and announced a new collaboration agreement with Roche to advance research into degrader-antibody conjugate (DAC) modalities. This strategic partnership validates C4T’s targeted protein degradation (TPD) platform and marks a crucial step in accelerating the development of next-generation anti-cancer therapies. Combining both companies’ expertise is expected to yield novel approaches for diseases intractable with existing treatments.

In Depth

Key Findings

C4 Therapeutics (C4T) announced strong financial results for the second quarter of 2026 and, concurrently, disclosed a new collaboration agreement with Roche, a major pharmaceutical company, to advance research into degrader-antibody conjugate (DAC) modalities. This partnership signals the industry’s recognition of the significant potential inherent in C4T’s targeted protein degradation (TPD) technology.

Technical / Clinical Details

Degrader-antibody conjugates (DACs) represent a next-generation modality, applying the principles of antibody-drug conjugates (ADCs) to protein degraders. In this approach, an antibody targeting specific cell surface antigens delivers a degrader (a protein degradation-inducing agent) into the cell, where it then facilitates the degradation of target proteins within cancer cells. C4T leverages its proprietary TPD platform, which excels in designing small molecule degraders that selectively eliminate disease-associated proteins. The collaboration with Roche is expected to accelerate the development of new DAC candidates for difficult-to-treat cancers, by synergizing Roche’s extensive expertise in antibody development and oncology with C4T’s advanced TPD technology.

Background & Context

Targeted protein degradation (TPD) technology has emerged as a revolutionary drug discovery paradigm, enabling the targeting of “undruggable” proteins that were previously inaccessible with conventional small molecule inhibitors. DACs, by combining ADC and TPD technologies, aim to achieve maximal therapeutic efficacy and minimize side effects through highly specific delivery to cancer cells and potent intracellular action. A partnership with a major player like Roche further validates C4T’s technology and strengthens its leadership in the TPD field.

Strategic Significance & Outlook

This collaboration with Roche is a crucial strategic milestone for C4T, contributing to both the deepening of its pipeline and the diversification of its revenue streams. While DAC development is still in its early stages, its success holds the potential to bring about new breakthroughs in cancer treatment. As concrete DAC candidates from this partnership advance into preclinical and clinical development, their true therapeutic potential will become clearer, marking a significant evolution in oncology.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime